Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort

dc.contributor.authorBuzón Martín, Luis
dc.contributor.authorBernardino, José I.
dc.contributor.authorGalindo Puerto, María José
dc.contributor.authorMartín Torres, Juan
dc.contributor.authorAlemán Valls, María Remedios
dc.contributor.authorTorralba González de Suso, Miguel
dc.contributor.authorDíaz de Santiago, Alberto
dc.contributor.authorFanjul, Francisco
dc.contributor.authorRodríguez, Adrián
dc.contributor.authorCabello Úbeda, Alfonso
dc.contributor.authorPedrero Tomé, Roberto
dc.contributor.authorCrusells Canales, María José
dc.contributor.authorCalzado Isbert, Sonia
dc.contributor.authorAguilera García, María
dc.contributor.authorHidalgo Tenorio, Carmen
dc.contributor.authorMorano, Luis
dc.contributor.authorVinuesa García, David
dc.contributor.authorAndrés David, Carlos de
dc.contributor.authorBernal Morell, Enrique
dc.contributor.authorMartínez Álvarez, Rosa María
dc.contributor.authorCabello Clotet, Noemí
dc.contributor.authorTiraboschi, Juan Manuel
dc.contributor.authorGimeno García, Alejandra
dc.contributor.authorVivancos, María Jesús
dc.contributor.authorTroya, Jesús
dc.contributor.authorRelativity Cohort Group
dc.date.accessioned2026-07-01T11:32:46Z
dc.date.available2026-07-01T11:32:46Z
dc.date.issued2025-10-22
dc.date.updated2026-05-14T12:51:49Z
dc.description.abstractObjectives:Long-acting injectable cabotegravir and rilpivirine (LAI CAB+RPV) provides an alternative to daily therapy for people with HIV (PWH) with virologic suppression. Although genotypic testing is recommended before switching, its real-world clinical value is unclear. We assessed outcomes after switching to LAI CAB+RPV with or without available genotypes in the Spanish RELATIVITY cohort. Design:RELATIVITY is a multicenter, ambispective cohort study assessing the effectiveness and safety of LAI CAB+RPV in adults with HIV across 58 centers in Spain. Methods:Posthoc analysis of 3146 participants, focusing on the availability of genotypic resistance data before switching. Results:Of the 3146 participants, 53.5% (n = 1682) did not have genotypes available. The median follow-up was 13.3 months [interquartile range (IQR) 8.6, 18.9] in the no-genotype group and 14.9 months (IQR 9.0, 19.2) in the genotype group (P = 0.003). Both groups maintained high virological suppression rates (>93%) up to the 23rd month of follow-up, with no significant differences observed in virological or immunological outcomes. Virologic failure rates (0.5% vs. 1.0%; P = 0.476) and permanent discontinuation rates (6.1% vs. 6.6%; P = 0.804) were similar. Of the 20 participants with virologic failure, 12 had genotype data. After resuming oral antiretroviral therapy, 8 of those with and 4 of those without the genotype achieved undetectable viral loads. Adherence to injection schedules and changes in body mass index were comparable. Conclusions:In this large real-world cohort, the absence of genotypic data did not affect LAI CAB+RPV effectiveness in virologically suppressed PWH. Limitations, including ambispective design, short follow-up, and low non-B subtype prevalence, may limit generalizability.
dc.format.extent14 p.
dc.format.mimetypeapplication/pdf
dc.identifier.issn1473-5571
dc.identifier.pmid41183264
dc.identifier.urihttps://hdl.handle.net/2445/230341
dc.language.isoeng
dc.publisherWolters Kluwer Health
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1097/QAD.0000000000004388
dc.relation.ispartofAIDS, 2025, vol. 40, num. 4, p. 414-427
dc.relation.urihttps://doi.org/10.1097/QAD.0000000000004388
dc.rightscc by-nc-nd (c) Buzón Martín, Luis et al., 2026
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceArticles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
dc.subject.classificationAntiretrovirals
dc.subject.classificationMedicació transdèrmica
dc.subject.otherAntiretroviral agents
dc.subject.otherTransdermal medication
dc.titleGenotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
genotyping_not_required_for_sustained.2.pdf
Mida:
714.12 KB
Format:
Adobe Portable Document Format